Business Description
Teva Pharmaceutical Industries Ltd
SIC : 2837
ISIN : IL0006290147
Total Employee Number:
32,842Compare
Compare
Traded in other countries / regions
TEVA.IsraelTEVA.USA0LER.UKTEV.GermanyT1EV34.BrazilTEVA N.MexicoTEVA.AustriaTEV.Bulgaria Description
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. Its generics business spans a broad portfolio of off-patent prescription drugs, over-the-counter products, and biosimilars, sold across North America, Europe, and other international markets, with the United States representing its largest single market. Beyond generics, Teva develops and markets specialty and innovative medicines, most notably in neurology, where it sells treatments for multiple sclerosis and movement disorders, and in immunology. The company also produces active pharmaceutical ingredients and provides contract manufacturing services. Through Anda, its US distribution arm, Teva supplies generic and specialty pharmaceuticals to pharmacies, clinics, and other healthcare providers. Revenue comes primarily from pharmaceutical product sales, supplemented by distribution and manufacturing services, with generic medicines accounting for the largest share of total sales.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.22 | |||||
Equity-to-Asset | 0.2 | |||||
Debt-to-Equity | 2.18 | |||||
Debt-to-EBITDA | 6.67 | |||||
Interest Coverage | 3.9 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 0.81 | |||||
Beneish M-Score | -2.49 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.3 | |||||
3-Year EPS without NRI Growth Rate | 5.2 | |||||
3-Year FCF Growth Rate | 1.7 | |||||
3-Year Book Growth Rate | -0.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 1.98 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 81.92 | |||||
9-Day RSI | 78.56 | |||||
14-Day RSI | 76.73 | |||||
3-1 Month Momentum % | -6.39 | |||||
6-1 Month Momentum % | 0.14 | |||||
12-1 Month Momentum % | 98.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.88 | |||||
Quick Ratio | 0.67 | |||||
Cash Ratio | 0.23 | |||||
Days Inventory | 145.45 | |||||
Days Sales Outstanding | 75.76 | |||||
Days Payable | 112.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.2 | |||||
Shareholder Yield % | 2.26 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 52.47 | |||||
Operating Margin % | 18.78 | |||||
Net Margin % | 4.08 | |||||
EBITDA Margin % | 14.61 | |||||
FCF Margin % | 15.74 | |||||
OCF Margin % | 19.12 | |||||
ROE % | 9.3 | |||||
ROA % | 1.76 | |||||
ROIC % | 9.23 | |||||
3-Year ROIIC % | -41.57 | |||||
ROC (Joel Greenblatt) % | 33 | |||||
ROCE % | 5.72 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 65.98 | |||||
Forward PE Ratio | 12.85 | |||||
PE Ratio without NRI | 24.98 | |||||
PS Ratio | 2.49 | |||||
PB Ratio | 7.69 | |||||
Price-to-Free-Cash-Flow | 32.1 | |||||
Price-to-Operating-Cash-Flow | 22.78 | |||||
EV-to-EBIT | 34.45 | |||||
EV-to-Forward-EBIT | 18.25 | |||||
EV-to-EBITDA | 21.49 | |||||
EV-to-Forward-EBITDA | 14.05 | |||||
EV-to-Revenue | 3.26 | |||||
EV-to-Forward-Revenue | 3.44 | |||||
EV-to-FCF | 20.71 | |||||
Price-to-GF-Value | 2.38 | |||||
Price-to-Projected-FCF | 4.52 | |||||
Price-to-Median-PS-Value | 3.67 | |||||
Earnings Yield (Greenblatt) % | 2.9 | |||||
FCF Yield % | 5.85 | |||||
Forward Rate of Return (Yacktman) % | 3.15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:TEVA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Teva Pharmaceutical Industries Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 17,339 | ||
| EPS (TTM) ($) | 0.6 | ||
| Beta | 0.57 | ||
| 3-Year Sharpe Ratio | 0.83 | ||
| 3-Year Sortino Ratio | 2.11 | ||
| Volatility % | 66.73 | ||
| 14-Day RSI | 76.73 | ||
| 14-Day ATR ($) | 15.311631 | ||
| 20-Day SMA ($) | 33.7185 | ||
| 12-1 Month Momentum % | 98.32 | ||
| 52-Week Range ($) | 14.32 - 39.7 | ||
| Shares Outstanding (Mil) | 1,166.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Teva Pharmaceutical Industries Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Teva Pharmaceutical Industries Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-03 | In 134 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-01-28 08:00 | In 129 days | ||
| Fourth quarter earnings results for 2026 | 2027-01-28 07:00 | In 129 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 08:00 | In 45 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 07:00 | In 45 days | ||
| Guidance call for 2026 | 2026-09-23 05:05 | In 2 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-14 08:30 | -- | ||
| IL-15 Celiac Disease Phase 2a Topline Results - Conference Call | 2026-09-02 08:00 | -- | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 08:00 | -- | ||
| Second quarter earnings results for 2026 | 2026-07-29 | -- |
Show
Entries
Teva Pharmaceutical Industries Ltd Frequently Asked Questions
What is Teva Pharmaceutical Industries Ltd(TEVA)'s stock price today?
The current price of TEVA is $40.06. The 52 week high of TEVA is $39.70 and 52 week low is $14.32.
When is next earnings date of Teva Pharmaceutical Industries Ltd(TEVA)?
The next earnings date of Teva Pharmaceutical Industries Ltd(TEVA) is 2026-11-05 Est..
Does Teva Pharmaceutical Industries Ltd(TEVA) pay dividends? If so, how much?
Teva Pharmaceutical Industries Ltd(TEVA) does not pay dividend.
Press Release
Headlines
See More- 1
Sep 10, 2026
Teva prices $4.9B senior notes to refinance higher-cost debt
Seeking Alpha • 5:48am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers